Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma
Autor: | Robert Principato, Stanley E. Order, Albert S. DeNittis, Karen Martz, Wayne S. Court, L. S. Zeiger, Jeffry A. Siegel, Elizabeth Johnson |
---|---|
Rok vydání: | 2002 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular medicine.medical_treatment Gastroenterology Drug Administration Schedule Route of administration Internal medicine Carcinoma medicine Humans Infusions Intra-Arterial Survival analysis Aged Cisplatin Aged 80 and over Chemotherapy business.industry Liver Neoplasms virus diseases General Medicine Middle Aged medicine.disease Survival Analysis Radiation therapy Regimen Oncology Hepatocellular carcinoma Female business Nuclear medicine medicine.drug |
Zdroj: | Cancer investigation. 20(5-6) |
ISSN: | 0735-7907 |
Popis: | Intraarterial delivery of 50 mg/m2 cisplatinum on a monthly basis is a well-tolerated regimen for patients with nonresectable hepatoma. The selective uptake of cisplatinum delivered intraarterially suggests other selective intraarterial protocols would be of use in regional cancers treated with cisplatinum.Sixty-seven patients with nonresectable hepatoma were treated with hepatic artery infusions (HAI) of 50 mg/m2 cisplatinum on a monthly basis.Forty-eight patients received an initial course of whole liver external radiation with intravenous (i.v.) cisplatinum 50 mg/m2. Nineteen patients did not receive radiation and received HAI cisplatinum only. All patients then received HAI cisplatinum at 50 mg/m2 on a monthly basis. Six patients were given a tracer dose of radioactive 195m cisplatinum for quantitation by the HAI and i.v. routes.Monthly HAI cisplatinum was well tolerated and could be repeated indefinitely. Median survival for primarily treated nonresectable hepatomas was 12 months [alpha fetoprotein (AFP) elevated] and 17.5 months (AFP negative). Radioactive cisplatinum given by HAI yielded 34-55% tumor uptake of cisplatinum vs.5% by i.v. delivery.Hepatic intraarterial cisplatinum at 50 mg/m2 is a well-tolerated monthly regimen for patients with nonresectable hepatoma. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |